HIV/AIDS Drug Development Program

Cannabis Science Research Foundation is embarking on a drug development program to inhibit HIV replication in HIV patients. The HIV virus has developed a resistance to many of the current available therapies, but the Foundation is working hard on finding an alternative to this phenomenon to prolong the life of HIV patients.

Early Research Provides Clue to New Strategy for Inhibiting HIV Replication

TAT is an HIV gene, increasing the level of transcription of the HIV dsDNA. Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by the National Institutes of Health’s (NIH) Clinical and Translational Science Award Grant.

The Foundation's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies.

HIV’s ability to mutate and reproduce itself even in the presence of antiretroviral drugs, has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV, and is creating a pressing need to develop new HIV drugs.

The Foundation will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions.The Foundation will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).